BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/12/2022 4:24:12 AM | Browse: 797 | Download: 2279
 |
Received |
|
2022-06-08 04:30 |
|
Peer-Review Started |
|
2022-06-08 04:34 |
|
First Decision by Editorial Office Director |
|
2022-09-02 22:05 |
|
Return for Revision |
|
2022-09-02 22:05 |
|
Revised |
|
2022-09-10 12:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-09-23 03:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-09-23 16:15 |
|
Articles in Press |
|
2022-09-23 16:15 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-10-08 13:01 |
|
Publish the Manuscript Online |
|
2022-10-12 04:24 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yun-Zi Wu, Ming Wu, Xiao-Hao Zheng, Bing-Zhi Wang, Li-Yan Xue, Shi-Kang Ding, Lin Yang, Jian-Song Ren, Yan-Tao Tian and Yi-Bin Xie |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| CAMS Initiative for Innovative Medicine |
2016-I2M-1-007 |
|
| Corresponding Author |
Yi-Bin Xie, MD, Doctor, Doctor, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan South Lane, Chaoyang District, Beijing 100021, China. yibinxie_2003@163.com |
| Key Words |
Sustained-release 5-fluorouracil implants; Gastric cancer; 5-year survival rate; Safety; Prognostic factor; R0 radical resection |
| Core Tip |
Intraoperative drug administration shows promise in preventing the recurrence of gastric cancer. Sustained-release 5-fluorouracil (5-FU) implant is a new convenient and continuous drug release method that ensures locally high drug concentration for approximately 1 mo. 5-FU implants are widely used to treat various gastric tumors. However, presently, only retrospective research and a small-scale clinical study conducted in China have reported on its use in patients with gastric cancer. In our real-world study, we collected complete datasets, making this the largest study in China. Unfortunately, 5-FU implants did not improve the long-term survival of gastric cancer patients. |
| Publish Date |
2022-10-12 04:24 |
| Citation |
Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
|
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i38.5589 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
